2 active not recruiting, 2 completed, 1 recruiting, 1 terminated. 4 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Active not recruiting 2, Completed 1, Recruiting 1 |
| Phase 2 | 4 | Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow Refractory Angioimmunoblastic T-Cell Lymphoma: new trials by email Literature Review of Refractory Angioimmunoblastic T-Cell Lymphoma trials Research Report on Refractory Angioimmunoblastic T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL Oral azacitidine, Romidepsin, Bendamustine - Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma | Phase 3 | Completed | The Lymphoma Academic Research Organisation | 86 | 2018-11-09 | 2026-04-23 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
Immunoblastic Lymphadenopathy (7) · Lymphoma, T-Cell (6) · Lymphoma, Large-Cell, Anaplastic (5) · Mycosis Fungoides (5) · Enteropathy-Associated T-Cell Lymphoma (4) · Lymphoma, T-Cell, Cutaneous (2) · Subcutaneous panniculitis-like T-cell lymphoma (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · HTLV-I Infections (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphadenopathy (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma, T-Cell, Cutaneous (3) · Hematologic Diseases (2) · Leukemia (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1)
pembrolizumab (3) · romidepsin (3) · Depsipeptides (2) · Lactones (2) · Nivolumab (2) · 10-propargyl-10-deazaaminopterin (1) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Biopsy (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Cyclophosphamide (1) · Disulfides (1) · Etoposide (1) · Gemcitabine (1)
M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · City of Hope Medical Center (1) · Northwestern University (1) · The Lymphoma Academic Research Organisation (1)
United States (6) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · United Kingdom (1)
Alex F Herrera (1) · Jonathan Moreira, MD (1) · Joselle Cook, M.B.B.S. (1) · Michelle Fanale (1) · Nora Bennani, M.D. (1) · Stephen Ansell (1) · Swaminathan P Iyer, MD (1)
PMID 29622656, PMID 35175355, PMID 35750419, PMID 36898933, PMID 38796193
P30CA015083 (1), P30CA016672 (1), P30CA060553 (1), P50CA186781 (1), R01CA262613 (1)